Navigation Links
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Date:9/10/2008

Non-stimulant drug addresses wide range of symptoms of ADHD

DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.

The study showed that the new drug, Clonicel, achieved statistically significant improvement over placebo in reducing an aggregate of 18 ADHD symptoms listed by the American Psychiatric Association and used by physicians to diagnose and classify the condition.

"This is the first study to validate the potential for a long-acting version of clonidine -- a widely used hypertension drug -- as a safe and effective treatment for ADHD," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals, a small Durham start-up that initiated and coordinated the multicenter trial.

Previous studies of clonidine have indicated that the drug diminishes select symptoms of ADHD, but these studies have been small and inconclusive, Khayrallah said. Moreover, clonidine carries bothersome side effects that have limited its use, including a peak of drowsiness when the drug is absorbed and a subsequent rebound of symptoms when drug levels subside.

Addrenex scientists developed Clonicel to reduce these side effects and treat specific ADHD symptoms that may occur when the body's adrenergic system is in overdrive, producing excessive levels of the stress hormone adrenaline. Such symptoms include emotional outbursts, mood swings, insomnia and hyperreactivity to stress.

"We conducted a well-powered, randomized clinical trial to demonstrate that Clonicel may be effective on its own in treating a multitude of ADHD symptoms, with a favorable side effect profile," said Khayrallah. "We're very excited with the positive data we obtained, and we intend for this study to serve as part of the basis for review
'/>"/>

SOURCE Addrenex
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Holdings, Inc. today announced that it has been na...Technology Council (NJTC), a 1,200-member non-prof...tworking opportunities, information and advocacy f...earned the award based on criteria including marke... , , "We are delighted that the New Jersey ...
(Date:11/20/2008)... The following is being released by Center for Hea...AIDS Day Audio Media Conference , , WHEN:... EST , Call-in number: 1-800-949-8476 , RSVP...1xe41i2yre8rs , , WHY: With new HIV infe... treatment worldwide, advocates are calling on the...
(Date:11/20/2008)...GlaxoSmithKline (NYSE: ...and Drug Administration (FDA) granted accelerated ...atment of thrombocytopenia in patients with chroni...P) who have had an insufficient response to cortic...roval is a significant milestone for PROMACTA and ...
(Date:11/20/2008)...ire-FirstCall/ -- Arpida (SWX:,ARPN) announced to...ee of the,U.S. Food and Drug Administration (FDA)...enous iclaprim, an antibiotic currently in develop...ed skin and skin structure infections,(cSSSIs), i...phylococcus,aureus (MRSA). , Arpida remain...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Direct Relief International Aims California Fire Response at Health Concerns 4445 1Direct Relief International Aims California Fire Response at Health Concerns 4445 2Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion 4442 1Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion 4442 2IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 1IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 2IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 3Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County 4440 1Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County 4440 2
....Y.--(BUSINESS WIRE)--Jun 4, 2007 - Acorda,Therape... the,Company presented a "meta-analysis" or combin...R in multiple sclerosis during a,poster session at...,in MS (ACTRIMS) Meeting in Washington, D.C. on Sa...onsistent Improvement in Walking,Speed on the Time...
...SINESS WIRE)--Jun 4, 2007 - Cytogen Corporation,(N...trials,demonstrating that QUADRAMET (samarium Sm-1...d to prostate cancer patients who are also,receivi...-Aventis).,Clinical data also support further eval...t of prostate cancer in a Phase 2 program.,The res...
Other Medicine Technology:Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 2Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 3Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7
(Date:11/22/2008)...0 don,t do enough to protect themselves from strok...ealthDay News) -- It,s one of medicine,s mantras: ...ower it will have a dramatic impact on your risk o...ent of people with high blood pressure still aren,...g to a U.S. Centers for Disease Control and Preven...
(Date:11/21/2008)...NTY, Calif., Nov. 21 Album Creativ...rm, launches a new program offering big brand mark...ken the large, expensive ad agency process and ser...a very hands-on approach," says Matt Parker, Creat...combines experience and proven brand-building tech...
(Date:11/21/2008)...ASSEE, Fla. -- A Florida State University College ... discovered an important new layer of regulation i...reater understanding of the way cancer begins. , ...es at the College of Medicine, said the findings w... and could lead to the design of new drugs that ki...
(Date:11/21/2008)...iz., Nov. 21 The Provide...nnounced that Craig A. Norris, the Company,s,Chie...pany,s Board of,Directors. Mr. Norris, appointme...nation of Steven I. Geringer and returns the board...y committee of the Board. , Mr. Norris, age...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3
...rkable for its ability to live in the strong acid ...ccoli is powerful against the bacterium that is li.../ It's now well established that this microbe is r...Clearing it with antibiotics is an important form ...
...ggest that, some women who develop gestational dia...en with certain chromosomal abnormalities However,...tself a risk factor for these types of defects sin...l before gestational diabetes typically develops./...
... study on seedless green grapes which caused a sal...x Western states last summer and fall. Researchers...nella serotype senftenberg// most often found in m...to people through grapes. Dr.Alicia, at the Intern...
...utting their lives at risk because they fail to ex...embarrassed to consult their general practitioner ... their argument on a case study involving a young...t and suffered minor injuries. Four days later he ...
Other Medicine News:Health News:Gestational Diabetes linked to Chromosomal defici 2Health News:Grapes, Melons Implicated in Outbreaks 2Health News:Patients with testicular cancer dying through unfamiliarity 2